dpp4 and glp-1 combination Mechanism of Action of GLP-1RAs DPP-4 inhibitors. DPP-4 inhibitors GLP-1 Receptor Agonists – Peripheral

A new drug called donanemab, designed to treat patients with Alzheimers and which gained FDA approval in July 2024, has blockbuster potential for Eli Lilly

It would be in a really small niche circuit, whereas now it is advertised and promoted, and companies are shouting about it, which I personally dont agree with

Scandinavian researchers gave people rice pudding with and without one or three grams of cinnamon, which is about a third of a teaspoon, or a full teaspoon

More info Share & earn

The completion of the trial allows Lilly to seek regulatory approval and potentially launch the next-generation drug in 2027 as it competes with Novo Nordisk in the obesity treatment market

Those days will total a little higher than shown